Science Times Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.

Press releases published on March 4, 2026

SGH Partners With Redesign Health to Strengthen the Healthcare Innovation Ecosystem
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
LB Pharmaceuticals to Participate in Upcoming March Investor Events
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rigetti Computing Reports Fourth Quarter and Full-Year 2025 Financial Results
red violet Announces Fourth Quarter and Full Year 2025 Financial Results
Pulmonx Announces Closing of up to $60 Million Credit Facility
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
Coherent Launches 224Gbps Quad TIA for Next-Generation AI and Cloud Infrastructure
Alto Ingredients, Inc. Reports Fourth Quarter and Year-end 2025 Results
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Galapagos Receives Transparency Notifications from Bank of America
Galapagos ontvangt transparantieverklaringen van Bank of America
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Share this page:

Sign up for:

Science Times Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.